[{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"a37af355-2625-4415-ae7c-59d702230ad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776917","created_at":"2021-01-18T13:37:02.048Z","updated_at":"2024-07-02T16:35:10.661Z","phase":"Phase 1","brief_title":"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer","source_id_and_acronym":"NCT02776917","lead_sponsor":"Barbara Parker, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 07/13/2021","primary_completion_date":" 07/13/2021","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-10"},{"id":"2825ea8b-9459-479e-9752-18cd9b5e3122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860676","created_at":"2021-01-18T14:02:32.507Z","updated_at":"2024-07-02T16:37:01.504Z","phase":"Phase 1","brief_title":"Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961","source_id_and_acronym":"NCT02860676","lead_sponsor":"University of California, San Diego","biomarkers":" CD19 • CD5","pipe":"","alterations":" ","tags":["CD19 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 11/03/2016","start_date":" 11/03/2016","primary_txt":" Primary completion: 02/27/2018","primary_completion_date":" 02/27/2018","study_txt":" Completion: 05/22/2018","study_completion_date":" 05/22/2018","last_update_posted":"2019-03-20"},{"id":"8ac1e017-da1c-4007-8416-53084f3ac3fb","acronym":"CIRLL study","url":"https://clinicaltrials.gov/study/NCT03420183","created_at":"2021-01-18T16:52:25.006Z","updated_at":"2024-07-02T16:37:02.627Z","phase":"Phase 1b","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03420183 - CIRLL study","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2019-02-20"}]